Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 29.08
NVIV's Cash to Debt is ranked lower than
52% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. NVIV: 29.08 )
Ranked among companies with meaningful Cash to Debt only.
NVIV' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 40.89 Max: No Debt
Current: 29.08
F-Score: 4
Z-Score: 14.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -119.26
NVIV's ROE (%) is ranked lower than
86% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. NVIV: -119.26 )
Ranked among companies with meaningful ROE (%) only.
NVIV' s ROE (%) Range Over the Past 10 Years
Min: -775.86  Med: -325.82 Max: -30.97
Current: -119.26
-775.86
-30.97
ROA (%) -81.60
NVIV's ROA (%) is ranked lower than
83% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. NVIV: -81.60 )
Ranked among companies with meaningful ROA (%) only.
NVIV' s ROA (%) Range Over the Past 10 Years
Min: -1218.1  Med: -233.77 Max: 42.86
Current: -81.6
-1218.1
42.86
ROC (Joel Greenblatt) (%) -2146.26
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. NVIV: -2146.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVIV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3330.38  Med: -1661.69 Max: 334.39
Current: -2146.26
-3330.38
334.39
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

NVIV Guru Trades in

NVIV Guru Trades in

NVIV Guru Trades in

Q1 2016

NVIV Guru Trades in Q1 2016

Jim Simons 31,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:FLKS, NAS:VTVT, NAS:ITEK, NAS:BOLT, OTCPK:BBLG, NAS:CCXI, AMEX:PFNX, NAS:FOMX, NAS:CYNA, NAS:CBMG, NAS:ENZY, NAS:ABUS, NAS:QURE, OTCPK:DGJI, OTCPK:HNSBF, NAS:VTL, NAS:IMMU, AMEX:MDGN, NAS:IDRA, NAS:OSIR » details
Traded in other countries:04IA.Germany,
InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.

Ratios

vs
industry
vs
history
P/B 4.53
NVIV's P/B is ranked lower than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. NVIV: 4.53 )
Ranked among companies with meaningful P/B only.
NVIV' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 67.4
Current: 4.53
0
67.4
Current Ratio 9.76
NVIV's Current Ratio is ranked higher than
76% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NVIV: 9.76 )
Ranked among companies with meaningful Current Ratio only.
NVIV' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.70 Max: 14.81
Current: 9.76
0.14
14.81
Quick Ratio 9.76
NVIV's Quick Ratio is ranked higher than
76% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. NVIV: 9.76 )
Ranked among companies with meaningful Quick Ratio only.
NVIV' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.70 Max: 14.81
Current: 9.76
0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.74
NVIV's Price/Net Cash is ranked higher than
54% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. NVIV: 4.74 )
Ranked among companies with meaningful Price/Net Cash only.
NVIV' s Price/Net Cash Range Over the Past 10 Years
Min: 4.72  Med: 17.21 Max: 48
Current: 4.74
4.72
48
Price/Net Current Asset Value 4.63
NVIV's Price/Net Current Asset Value is ranked higher than
53% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. NVIV: 4.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVIV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.44  Med: 16.52 Max: 34.94
Current: 4.63
4.44
34.94
Price/Tangible Book 4.52
NVIV's Price/Tangible Book is ranked lower than
55% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. NVIV: 4.52 )
Ranked among companies with meaningful Price/Tangible Book only.
NVIV' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.83  Med: 14.02 Max: 29.63
Current: 4.52
3.83
29.63
Earnings Yield (Greenblatt) (%) -16.69
NVIV's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. NVIV: -16.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVIV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -45.99  Med: 0.00 Max: 1000
Current: -16.69
-45.99
1000

More Statistics

EPS (TTM) $ -0.89
Beta3.21
Short Percentage of Float8.94%
52-Week Range $3.50 - 17.65
Shares Outstanding (Mil)31.91

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.08 -1.16 -0.89
EPS w/o NRI ($) -1.08 -1.16 -0.89
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society Jun 23 2016
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society Jun 23 2016
InVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First... Jun 22 2016
InVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First... Jun 22 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Jun 08 2016
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors Jun 08 2016
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors Jun 08 2016
Invivo Therapeutics Holdings Corp. :NVIV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6,... Jun 06 2016
6 Breakout Stocks Under $10 Set to Soar May 31 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws;... May 27 2016
InVivo Therapeutics Featured on CBS Radio Affiliate May 26 2016
InVivo Therapeutics Featured on CBS Radio Affiliate May 26 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial... May 25 2016
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal... May 18 2016
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal... May 18 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure May 18 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Financials May 13 2016
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE... May 11 2016
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE... May 11 2016
NVIV: Cash Sufficient, Progress Consistent May 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)